

Leuven, 17 DECEMBER 2020

To whom it may concern.

Concerning clinical trial with reference EudraCT 2009-018228-14:

In order to comply with the European Commission Guideline 2012/C 302/03 on reporting of results to the EudraCT clinical trials database, the following statement is made for EudraCT 2009-018228-14 "HGG-2010. A phase IIb prospective placebo-controlled double blind randomized clinical trial for the treatment of patients with newly diagnosed glioblastoma multiforme with tumor vaccination as "add-on therapy" to standard primary treatment":

- This clinical trial was terminated early,
- This trial was interrupted and has no reportable results due to trial inconsistencies,
- This trial was prematurely ended with end of trial date on 2015-09-30.

On behalf of the sponsor,

Professor Steven De Vleeschouwer, MD PhD

UZ Leuven – Gasthuisberg  
Neurosurgery  
Herestraat 49  
B-3000 Leuven  
Belgium